0.2891
price up icon5.13%   0.0141
pre-market  Pre-market:  .28   -0.0091   -3.15%
loading
Processa Pharmaceuticals Inc stock is traded at $0.2891, with a volume of 12.18M. It is up +5.13% in the last 24 hours and up +20.61% over the past month. Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
See More
Previous Close:
$0.275
Open:
$0.27
24h Volume:
12.18M
Relative Volume:
0.92
Market Cap:
$4.08M
Revenue:
-
Net Income/Loss:
$-11.53M
P/E Ratio:
-0.06
EPS:
-4.82
Net Cash Flow:
$-11.12M
1W Performance:
+11.19%
1M Performance:
+20.61%
6M Performance:
-66.81%
1Y Performance:
-85.32%
1-Day Range:
Value
$0.266
$0.2935
1-Week Range:
Value
$0.2315
$0.33
52-Week Range:
Value
$0.15
$3.10

Processa Pharmaceuticals Inc Stock (PCSA) Company Profile

Name
Name
Processa Pharmaceuticals Inc
Name
Phone
443-776-3133
Name
Address
7380 COCA COLA DRIVE, HANOVER
Name
Employee
13
Name
Twitter
Name
Next Earnings Date
2024-11-11
Name
Latest SEC Filings
Name
PCSA's Discussions on Twitter

Compare PCSA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
PCSA
Processa Pharmaceuticals Inc
0.2891 4.08M 0 -11.53M -11.12M -4.82
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
450.27 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
522.27 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.00 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
568.06 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
266.80 28.51B 3.81B -644.79M -669.77M -6.24

Processa Pharmaceuticals Inc Stock (PCSA) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-25-24 Initiated H.C. Wainwright Buy

Processa Pharmaceuticals Inc Stock (PCSA) Latest News

pulisher
Jun 18, 2025

Processa Pharmaceuticals Announces Public Offering Pricing - TipRanks

Jun 18, 2025
pulisher
Jun 18, 2025

Processa inks licensing deal with Intact for gastroparesis drug By Investing.com - Investing.com India

Jun 18, 2025
pulisher
Jun 17, 2025

Processa Pharmaceuticals (PCSA) Sets Public Offering Price at $0 - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Processa Pharmaceuticals Signs Binding Term Sheet Granting - GlobeNewswire

Jun 17, 2025
pulisher
Jun 17, 2025

Processa Pharmaceuticals (PCSA) Enters Licensing Agreement for G - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Processa Pharmaceuticals Prices of $7 Million Public Offering - citybiz

Jun 17, 2025
pulisher
Jun 17, 2025

Processa inks licensing deal with Intact for gastroparesis drug - Investing.com

Jun 17, 2025
pulisher
Jun 17, 2025

Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering | PCSA Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Processa Pharmaceuticals (PCSA) Announces Public Offering Pricin - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Processa Pharmaceuticals Prices $7 Million Public Offering - MarketScreener

Jun 17, 2025
pulisher
Jun 17, 2025

Processa Pares Gains on Equity Offer News - MarketWatch

Jun 17, 2025
pulisher
Jun 17, 2025

Processa Pharmaceuticals (PCSA) Announces Public Offering Pricing | PCSA Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Processa sells 28M shares at 25c in public offering - TipRanks

Jun 17, 2025
pulisher
Jun 17, 2025

Processa sees 28M shares at 25c in public offering - TipRanks

Jun 17, 2025
pulisher
Jun 17, 2025

Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering - GlobeNewswire

Jun 17, 2025
pulisher
Jun 17, 2025

Processa Pharmaceuticals Secures $7M Funding: Next-Generation Cancer Drug Trial Gets Green Light - Stock Titan

Jun 17, 2025
pulisher
Jun 17, 2025

Processa Pharmaceuticals Announces Licensing Deal with Intact - TipRanks

Jun 17, 2025
pulisher
Jun 17, 2025

Processa Pharmaceuticals (PCSA) Shares Soar 150% On Gastroparesis Drug Deal - Benzinga

Jun 17, 2025
pulisher
Jun 17, 2025

Processa Pharmaceuticals Grants Intact Therapeutics Exclusive Option to License Gastroparesis Drug Candidate; Shares Rise - marketscreener.com

Jun 17, 2025
pulisher
Jun 17, 2025

Processa Pharmaceuticals Skyrockets on Game-Changing Gastroparesis Deal - RagingBull

Jun 17, 2025
pulisher
Jun 17, 2025

Processa Pharmaceuticals signs binding term sheet with Intact Therapeutics - TipRanks

Jun 17, 2025
pulisher
Jun 17, 2025

Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate - Yahoo Finance

Jun 17, 2025
pulisher
Jun 17, 2025

Processa Pharmaceuticals (NASDAQ:PCSA) Trading Down 12.9% – Time to Sell? - Defense World

Jun 17, 2025
pulisher
Jun 16, 2025

Navigating PCSA’s Stock Market Maze: Ups and Downs in 2023 - investchronicle.com

Jun 16, 2025
pulisher
Jun 14, 2025

Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025 - GlobeNewswire

Jun 14, 2025
pulisher
Jun 13, 2025

Processa Pharmaceuticals (PCSA) Prepares for Strategic Insights at BIO Convention 2025 | PCSA Stock News - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Processa to engage potential partners, investors at BIO International Convention - TipRanks

Jun 13, 2025
pulisher
Jun 13, 2025

Processa Pharmaceuticals to Engage Potential Partners and Invest - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

PCSA Stock Placement by H.C. Wainwright & Co. | PCSA Stock News - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Processa Pharmaceuticals to Showcase Next Generation Cancer Therapies at 2025 BIO International Convention - Nasdaq

Jun 13, 2025
pulisher
Jun 13, 2025

Next-Gen Cancer Drug Developer Processa Pharma Eyes Strategic Partners at Major BIO Convention - Stock Titan

Jun 13, 2025
pulisher
May 31, 2025

Processa Pharmaceuticals presents cancer drug advances at ASCO By Investing.com - Investing.com South Africa

May 31, 2025
pulisher
May 30, 2025

Processa Pharmaceuticals (PCSA) Highlights Cancer Drug Advances at ASCO 2025 | PCSA Stock News - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Processa Pharmaceuticals Announces Presentation and Publication - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting | PCSA Stock News - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Processa Pharmaceuticals presents cancer drug advances at ASCO - Investing.com Australia

May 30, 2025
pulisher
May 30, 2025

Processa Pharmaceuticals Highlights Next Generation Cancer Therapies with Three Accepted Abstracts at 2025 ASCO Annual Meeting - Nasdaq

May 30, 2025
pulisher
May 30, 2025

Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting - GlobeNewswire

May 30, 2025
pulisher
May 30, 2025

Latest Clinical Trial Data: Processa Presents 3 Cancer Treatment Breakthroughs at ASCO 2025 - Stock Titan

May 30, 2025
pulisher
May 24, 2025

Processa Pharmaceuticals (NASDAQ:PCSA) Stock Price Down 1.5% – What’s Next? - Defense World

May 24, 2025
pulisher
May 09, 2025

Processa Pharmaceuticals faces Nasdaq delisting risk over share price - MSN

May 09, 2025
pulisher
May 08, 2025

Processa Pharmaceuticals Announces Launch of Website (www.Necrobiosislipoidicastudy.com) to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499 - Barchart.com

May 08, 2025
pulisher
May 02, 2025

PCSAProcessa Pharmaceuticals Inc Latest Stock News & Market Updates - Stock Titan

May 02, 2025
pulisher
May 02, 2025

There is no way Processa Pharmaceuticals Inc (PCSA) can keep these numbers up - Sete News

May 02, 2025
pulisher
May 02, 2025

Processa Pharmaceuticals (PCSA) Expected to Announce Earnings on Friday - Defense World

May 02, 2025
pulisher
May 01, 2025

Processa Pharmaceuticals Inc: Rising -91.68% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com

May 01, 2025
pulisher
Apr 30, 2025

Taking a Closer Look At Processa Pharmaceuticals Inc (PCSA) Following Its Recent Trade - knoxdaily.com

Apr 30, 2025
pulisher
Apr 24, 2025

Processa Pharmaceuticals Inc [PCSA] Shares Rise 8.43 % on Wednesday - knoxdaily.com

Apr 24, 2025
pulisher
Apr 24, 2025

Processa Pharmaceuticals stock hits 52-week low at $0.65 - MSN

Apr 24, 2025
pulisher
Apr 22, 2025

Processa Pharmaceuticals Inc (PCSA) can make a big difference with a little luck - Sete News

Apr 22, 2025
pulisher
Apr 21, 2025

A Closer Look at Processa Pharmaceuticals Inc (PCSA) Stock Gains - investchronicle.com

Apr 21, 2025

Processa Pharmaceuticals Inc Stock (PCSA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Processa Pharmaceuticals Inc Stock (PCSA) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Ng George K
Chief Executive Officer
Jan 27 '25
Buy
0.80
87,200
69,542
87,200
Young David
Pres. Research & Development
Jan 27 '25
Buy
0.80
124,500
99,289
205,405
Lin Patrick
Chief Business - Strategy Off
Jan 27 '25
Buy
0.80
43,500
34,691
43,500
$20.74
price up icon 0.29%
$36.14
price up icon 2.09%
$20.92
price up icon 2.60%
$105.90
price up icon 0.46%
$105.09
price up icon 2.02%
biotechnology ONC
$266.80
price up icon 3.61%
Cap:     |  Volume (24h):